SEC Form 4 · accession 0000886163-17-000081
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Higgins
Officer — Chief Executive Officer · Director
Period of report
Feb 23, 2008
Accepted (ET)
Jun 23, 2017 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 21, 2017 | M | 4,666 | $21.00 | A | 143,837 | D | |
| Common StockF1 | Jun 21, 2017 | S | 4,666 | $120.00 | D | 139,171 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $21.00 | Feb 23, 2008 | A | 4,666 | A | Feb 15, 2009 | Feb 23, 2018 | Common Stock | 4,666 | 4,666 | D |
| Employee Stock Option (right to buy)F1 | $21.00 | Jun 21, 2017 | M | 4,666 | D | Feb 15, 2009 | Feb 23, 2018 | Common Stock | 4,666 | 0 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on May 11, 2017, in accordance with Rule 10b5-1.
- F2On February 23, 2008, the Reporting Person was granted an option to purchase 4,666 shares of common stock. The option vested in full on February 15, 2009 based on the satisfaction of certain performance goals.